Certain Flu Shot Shipments Delayed 1-Month
Sanofi Pasteur influenza vaccine shipments are expected by November 2019
Sanofi’s influenza vaccine shipments for the 2019-2020 flu season will be delayed about 1-month, reported CNBC.
Sanofi said to CNBC on July 24, 2019, that all of their flu vaccine shipments are expected to be completed by the end of November 2019.
The company said this delay is related to the World Health Organization (WHO) delaying its decision to select which H3N2 virus strains would be included in the Northern Hemisphere vaccine.
“We are still on track to produce approximately 70 million doses of seasonal vaccine to support nationwide immunization campaigns,” Sanofi spokesperson Nicolas Kressmann said in a statement.
But, this Sanofi shipping delay may lead to reduced protection from the 2019-2020’s version from the flu.
The CDC recommends getting vaccinated early, ideally by the end of October, when the new version of the flu begins to spread in the Northern Hemisphere.
Furthermore, if you are visiting the Southern Hemisphere in 2019, their version of the flu shot may be different, but needed to protect you for those viruses.
Influenza viruses circulate year-round around the world, however, most of the time flu activity peaks between December and February in the USA.
Most people who get sick with flu will have a mild illness, will not need medical care or antiviral drugs and will recover in less than two weeks, says the CDC.
Some people, however, are more likely to get flu complications that can result in hospitalization and sometimes death. Pneumonia, bronchitis, sinus infections and ear infections are examples of flu-related complications.
The flu also can make chronic health problems worse.
For example, people with asthma may experience asthma attacks while they have flu and people with chronic congestive heart failure may experience a worsening of this condition triggered by flu, says the CDC.
Recent flu news
- Seqirus Ships Northern Hemisphere Flu Vaccines
- Flu Vaccines Expire on June 30th
- Xofluza Met Phase 3 Study Endpoint
- M-001 Universal Flu Vaccine Patient Application Accepted in Australia
- Universal Flu Shot Enters Phase 2 Clinical Study
The Sanofi delay comes on the heels of AstraZeneca’s announcement that its supply of FluMist Quadrivalent, a live attenuated influenza vaccine (LAIV) is expected to be limited this season due to manufacturing constraints.
In the USA, most pharmacies offer antiviral flu medicines and various influenza vaccines.
To help those without access to insurance programs, financial assistance programs can be found at Vaccine Discounts.
Physicians with questions on the shipping delay can contact their Sanofi Pasteur representative or call 1-800-VACCINE.
Sanofi is a global biopharmaceutical company focused on human health.